Key Takeaways
- 25% growth, stable margins: FY25 revenue reached ₹396.6 crores with PAT up 27%, while the EBITDA margin held at the 9%-11% band management expects to persist for 2-3 years.
- Order book doubled the revenue base: The confirmed order book stood at ~₹1,018 crores as of May 30, 2025, after booking ₹737 crores in new orders during FY25, setting up a 12-18 month execution runway.
- Commercial aerospace entry is now real: A Tier 1 OEM cleared the plant, completed an audit, and placed a first purchase order for process validation, opening a new vertical beyond the dominant defense franchise.
- Supply chain friction compressed H2 margins and swelled receivables: Middle Eastern conflict disrupted the Israeli supply chain that feeds 27%-30% of programs, pushing a larger share of manufacturing and receivables into the last quarter.
- What to watch next quarter: Whether the Fresenius Kabi medical device ramp translates into volume, any conversion from emergency defense procurement enquiries, and progress qualifying additional commercial aerospace OEMs.
Revenue & Profitability
- H2 drove the year: FY25 revenue of ₹396.6 crores was back-loaded, with H2 contributing ₹247 crores and growing 37% YoY, while the full-year growth landed at 25%.
- Profitability held its range: EBITDA grew 22% to ₹44.4 crores and PAT grew 27% to ₹19.4 crores, keeping the margin profile stable inside the 9%-11% band.
- H2 margin softness was mix-driven: A larger volume of slightly lower-margin boards shipped in the second half, diluting the blended margin even as absolute profit grew.
- Receivables spike was a timing issue, not a credit problem: Supply chain disruption concentrated manufacturing in the last quarter, inflating year-end receivables; the company says this has already smoothened out in Q1 FY26.
- Working capital target is 30% of sales: The ratio was close to 50% last year; management is targeting 30% and working with customers on advances to support the requirement.
Sumukh Narendra: "I would say that we are very confident that we would remain in the margin profile between 9% to 11%. There is also operational efficiencies as well as programs maturing which has allowed us to reach this margin profile. The next two, three years, I don't see the margin profile changing."
Order Book & Demand Visibility
- Order book crossed ₹1,000 crores: New order intake of ₹737 crores in FY25 pushed the confirmed order book to ~₹1,018 crores as of May 30, 2025, with execution spread over 12 to 18 months.
- FY26 inflow expected at similar levels: Management guided for ₹600-₹750 crores of new orders in FY26, which would grow the confirmed order book to ₹1,500-₹1,600 crores by year-end.
- Make in India now dominates: Approximately 80% of the order book is Make in India programs, with legacy offset programs having largely completed and no longer contributing a significant share.
- Export orders reached 22%-23% of the total: Growth was driven by licenses and approvals received for defense exports, plus a China-plus-One medical device opportunity for localization.
- Program delays are the structural risk: Management flagged that defense programs routinely face push-outs in sanctioning and reaching the series manufacturing stage, with some programs already delayed by two to three years.
Sumukh Narendra: "The risk is I would say the risk associated with any kind of a defense program, all these defense programs, there are push-outs. So, the major risk that we foresee is delays in the programs getting sanctioned and delays in the program getting to critical stage where we get into a series manufacturing stage."
Segment Mix & Vertical Expansion
| Vertical | Revenue Share | Commentary |
|---|---|---|
| Defense & Aerospace | 78% | Dominant franchise; commercial aerospace entry adds a new sub-vertical within the segment. |
| Industrial | 18.4% | Showed remarkable growth; details on specific sub-segments were not disclosed. |
| Medical Devices | ₹6.7 crores | Fresenius Kabi manufacturing agreement signed; first-phase certifications complete, ramp-up expected through FY26. |
- Commercial aerospace cleared its first hurdle: The company completed the certification process, and one foreign Tier 1 OEM audited and cleared the plant, placing a first purchase order to validate Vinyas's manufacturing process.
- More OEM qualifications in progress: Management is working with other OEMs for plant qualification and expects to provide further updates during the first half of FY26.
- Medical device ramp is beginning: Fresenius Kabi certifications and approvals are complete; the first few thousand units are expected to ship this year, with volume ramping over the financial year.
- Emergency procurement enquiries received: The Ministry of Defense has sent enquiries through the emergency procurement process; these are very fresh and no conversion has occurred yet.
Operations & Supply Chain
- High-mix, high-complexity is the moat: The company positions itself as a build-to-print manufacturer focused on low-to-medium volume, highly complex PCB assemblies and system assemblies for critical subsystems.
- Israeli supply chain exposure is material: 27% to 30% of programs depend on the Israeli supply chain for critical components and made-to-order parts, and the Middle Eastern conflict kept that supply chain on-and-off through FY25.
- Quality is tested before shipping: PCB assemblies and subsystems are fully tested and qualified before leaving the facility; rejection at the customer location is rare, and rework is possible if needed.
- Inventory management improved: Inventory levels have improved substantially compared to the prior year, despite the supply chain disruption.
- Optimal capacity utilization expected in FY27: Qualification and approval of a defense or aerospace facility typically takes 18-24 months; full optimal utilization of current capacity is expected next financial year.
Sumukh Narendra: "We are what we call as a high-mix, high-complexity assembly house. So, we make critical subsystems for our customers. And we focus on fairly complex both PCB assemblies as well as system assemblies for our customers. And we focus on low and medium volume manufacturing."
Margin Structure & Outlook
- Build-to-print economics cap the margin: All manufacturing is build-to-print; the differentiating factor is high mix and low volumes with higher complexity, but the value-add portion translates to an EBITDA of 10%-11%.
- Raw material costs are structurally higher: The complexity of the subsystems means raw material costs are significantly higher than typical EMS players, compressing the margin profile relative to revenue.
- System integration offers a small uplift: Management expects 2-3 basis points of gross margin improvement from moving into subsystem and system-level integration, but not enough to shift the overall band.
- Margin band seen as durable for 2-3 years: Operational efficiencies and program maturation have brought margins to the current 9%-11% range, and management does not expect the profile to change over the next two to three years.
- Build-to-spec has not yet contributed: Nothing substantial came through on the build-to-spec side in FY25, which could otherwise offer a path to structurally different margins.
Sumukh Narendra: "The mix. So, all of which end of the day is a build-to-print manufacturing that we do. The differentiating factor is we do high mix, low volumes. So, here, the complexity is higher, and we do lower volumes of the manufacturing. But at the end of the day, it is a build-to-print operation that we are doing. So, that is the reason for our margin profile."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue growth | 25% to 30% year-on-year growth | FY26 |
| EBITDA margin | Remain within 9% to 11% band | FY26 and next 2-3 years |
| Order inflow | ₹600 to ₹750 crores of new orders | FY26 |
| Order book | Grow confirmed order book to ₹1,500-₹1,600 crores | By end of FY26 |
| Optimal capacity utilization | Full optimal utilization of current capacity | FY27 |
| Working capital ratio | Reach approximately 30% of sales | No specific date; target stated |
| Fresenius Kabi ramp | First few thousand units shipping; ramp through the year | FY26 |
| Commercial aerospace OEM updates | Further updates on additional OEM qualifications | First half of FY26 |
Key Metrics
| Metric | Q4 FY25 |
|---|---|
| Revenue (FY25) | ₹396.6 cr, +25% YoY from ₹317 cr in FY24 |
| Revenue (H2 FY25) | ₹247.1 cr, +37% YoY |
| EBITDA (FY25) | ₹44.4 cr, +22% YoY, margin ~11% |
| EBITDA (H2 FY25) | ₹26.7 cr, +32% YoY, margin ~11% |
| Net profit (FY25) | ₹19.4 cr, +27% YoY from ₹15.3 cr in FY24 |
| Net profit (H2 FY25) | ₹12.4 cr, +28% YoY |
| EPS (FY25) | ₹15.43 |
| EPS (H2 FY25) | ₹9.86 |
| Revenue growth target (FY26) | 25% |
| EBITDA margin target (FY26) | 9% to 11% |
| Order book | ~₹1,018 cr as on May 30, 2025 |
| New orders booked (FY25) | ₹737 cr |
| Order inflow expected (FY26) | ₹600 to ₹750 cr |
| Expected order book by end of FY26 | ₹1,500 cr to ₹1,600 cr |
| Operating cash flow (FY25) | ₹8.8 cr positive |
| Defense & Aerospace revenue share | 78% of total revenue |
| Industrial revenue share | 18.4% of total revenue |
| Medical devices revenue | ₹6.7 cr |
| Export orders share | 22% to 23% of total orders |
| Current capacity utilization | ~35% |
| Revenue potential from current capacity | ₹1,200 cr to ₹1,400 cr |
| Order book execution timeline | 12 to 18 months |
| Supply chain dependency on Israel | 27% to 30% of programs |
| Target working capital | ~30% of revenue |
| Make in India share of order book | ~80% |
| Expected yearly CAPEX for critical programs | ₹2 cr to ₹3 cr |